MaxCyte, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
MaxCyte, Inc. (MXCT) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$13.62 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-13
- MaxCyte, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$8.87M.
- MaxCyte, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$4.75M.
- MaxCyte, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$9.60M.
- MaxCyte, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$12.42M.
- MaxCyte, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$44.63M.
- MaxCyte, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$41.05M.
- MaxCyte, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$37.92M.
- MaxCyte, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$23.57M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$8.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$13.62M 10-Q · filed 2026-08-13 | -$23.22M derived: sum of 3 quarters · filed 2026-08-13 | -$35.64M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$4.75M 10-Q · filed 2026-05-13 | -$14.35M derived: sum of 2 quarters · filed 2026-05-13 | -$26.76M derived: sum of 3 quarters · filed 2026-05-13 | -$39.12M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$9.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$22.01M derived: sum of 2 quarters · filed 2026-03-25 | -$34.37M derived: sum of 3 quarters · filed 2026-08-13 | -$44.63M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | -$12.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$24.77M derived: sum of 2 quarters · filed 2026-08-13 | -$35.03M 10-Q · filed 2025-11-13 | -$45.63M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$12.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$22.62M 10-Q · filed 2026-08-13 | -$33.22M derived: sum of 3 quarters · filed 2026-08-13 | -$44.77M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$10.26M 10-Q · filed 2026-05-13 | -$20.86M derived: sum of 2 quarters · filed 2026-05-13 | -$32.41M derived: sum of 3 quarters · filed 2026-05-13 | -$41.79M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | -$10.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$22.15M derived: sum of 2 quarters · filed 2026-03-25 | -$31.53M derived: sum of 3 quarters · filed 2026-03-25 | -$41.05M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | -$11.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$20.93M derived: sum of 2 quarters · filed 2025-11-13 | -$30.46M 10-Q · filed 2025-11-13 | -$35.74M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$9.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$18.90M 10-Q · filed 2025-08-06 | -$24.18M derived: sum of 3 quarters · filed 2025-08-06 | -$35.43M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | -$9.53M 10-Q · filed 2025-05-08 | -$14.80M derived: sum of 2 quarters · filed 2025-05-08 | -$26.05M derived: sum of 3 quarters · filed 2025-05-08 | -$36.57M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$16.53M derived: sum of 2 quarters · filed 2025-03-11 | -$27.04M derived: sum of 3 quarters · filed 2025-03-11 | -$37.92M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | -$11.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$21.76M derived: sum of 2 quarters · filed 2024-11-06 | -$32.65M 10-Q · filed 2024-11-06 | -$32.65M 10-Q · filed 2023-11-08 | -$37.45M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$10.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$21.39M 10-Q · filed 2024-08-06 | -$21.39M 10-Q · filed 2023-08-09 | -$26.20M derived: sum of 3 quarters · filed 2024-08-06 | -$32.64M derived: sum of 4 quarters · filed 2024-08-06 | |||
| 2023-03-31 | -$10.88M 10-Q · filed 2024-05-07 | -$10.88M 10-Q · filed 2023-05-10 | -$15.69M derived: sum of 2 quarters · filed 2024-05-07 | -$22.13M derived: sum of 3 quarters · filed 2024-05-07 | -$30.39M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | -$4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$11.24M derived: sum of 2 quarters · filed 2024-03-12 | -$19.50M derived: sum of 3 quarters · filed 2024-03-12 | -$23.57M 10-K · filed 2024-03-12 | -$23.57M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | -$6.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$14.69M derived: sum of 2 quarters · filed 2023-11-08 | -$18.76M 10-Q · filed 2023-11-08 | -$23.64M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | -$8.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$12.33M 10-Q · filed 2023-08-09 | -$17.20M derived: sum of 3 quarters · filed 2023-08-09 | -$19.88M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | -$4.07M 10-Q · filed 2023-05-10 | -$8.94M derived: sum of 2 quarters · filed 2023-05-10 | -$11.62M derived: sum of 3 quarters · filed 2023-05-10 | -$16.04M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$4.87M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$7.55M derived: sum of 2 quarters · filed 2023-03-15 | -$11.98M derived: sum of 3 quarters · filed 2023-03-15 | -$19.08M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | -$2.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$7.10M derived: sum of 2 quarters · filed 2022-11-09 | -$14.21M 10-Q · filed 2022-11-09 | -$16.86M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$4.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$11.53M 10-Q · filed 2022-08-10 | -$14.18M derived: sum of 3 quarters · filed 2022-08-10 | -$17.28M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$7.11M 10-Q · filed 2022-05-09 | -$9.76M derived: sum of 2 quarters · filed 2022-05-09 | -$12.86M derived: sum of 3 quarters · filed 2022-05-09 | |||||
| 2020-12-31 | -$2.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | -$5.75M derived: sum of 2 quarters · filed 2022-03-22 | -$11.82M 10-K · filed 2022-03-22 | |||||
| 2020-09-30 | -$3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$9.16M 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | -$6.07M 10-Q · filed 2021-09-13 | |||||||
| 2019-12-31 | -$12.89M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |